Skip to main
KLRS

Allovir Inc (KLRS) Stock Forecast & Price Target

Allovir Inc (KLRS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kalaris Therapeutics is a promising biopharmaceutical company with a strong focus on developing and commercializing therapeutics for prevalent retinal diseases, particularly wet AMD. With its novel drug, TH103, the company has demonstrated promising results in preclinical and Phase Ia studies, setting a strong foundation for potential future success. The potential for high sales in the wet AMD market, coupled with concerns about safety and efficacy of other treatments, make Kalaris Therapeutics an attractive investment opportunity.

Bears say

Kalaris Therapeutics is still in the early stages of development, and there are a few major hurdles to overcome before TH103 can be approved for commercialization. These include addressing issues with manufacturing and inflammation, gaining regulatory approval, and competing with other existing and potential treatments for wet AMD. Additionally, the company's financials show a significant decrease in revenue over the past few years, indicating potential financial struggles and a lack of success in bringing products to market. Based on these fundamental factors, it is likely that the stock of Kalaris Therapeutics will continue to underperform in the near future.

Allovir Inc (KLRS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allovir Inc (KLRS) Forecast

Analysts have given Allovir Inc (KLRS) a Buy based on their latest research and market trends.

According to 5 analysts, Allovir Inc (KLRS) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allovir Inc (KLRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.